Biotech Values

[jq1234]

>> Opdivo monotherapy ORR in PD-L1 “negative” was 41%, granted using a 5% cutoff.

In the same trial PD-L1 < 1% only:

Nivolumab monotherapy ORR=35%, nivolumab/ipilimumab ORR=54%, ipilimumab ORR=18%.

As I said before, melanoma and RCC are not right indications to test PD-L1- conversion to PD-L1+ theory based on small n single arm trial because PD1/PD-L1 are doing quite well as monotherapy in this population.